Dr. Eskelund on Outcomes of TP53-Mutated MCL

Christian Winther Eskelund, MD
Published: Wednesday, Oct 11, 2017



Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses outcomes for patients with TP53-mutated mantle cell lymphoma (MCL).

The significant findings of a study investigating TP53 mutations were that patients who had TP53 mutations did far worse than patients who had no mutations, states Eskelund. The median overall survival was 1.8 years versus 12 years for non-mutated patients.

TP53 is normally associated with poor outcomes in hematologic malignancies, making this an expected outcome, according to Eskelund.
 
SELECTED
LANGUAGE


Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses outcomes for patients with TP53-mutated mantle cell lymphoma (MCL).

The significant findings of a study investigating TP53 mutations were that patients who had TP53 mutations did far worse than patients who had no mutations, states Eskelund. The median overall survival was 1.8 years versus 12 years for non-mutated patients.

TP53 is normally associated with poor outcomes in hematologic malignancies, making this an expected outcome, according to Eskelund.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Year in Review™: Reflecting on Recent Evidence for the Treatment of Hematologic MalignanciesFeb 28, 20192.0
Publication Bottom Border
Border Publication
x